Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Admera Health launches Archer FusionPlex assay services

MDBR Staff Writer Published 03 June 2016

ArcherDX, the leader in NGS-based gene fusion detection, announced the addition of renowned molecular diagnostics company Admera Health as a Certified Service Provider (CSP) of Archer® FusionPlex assays.

Admera Health, headquartered in South Plainfield, New Jersey, provides diagnostic testing services across the continuum of patient care, including screening, diagnosis, treatment monitoring and patient management.

Its next-generation services include pharmacogenomics, inherited cardiovascular diseases and oncology tests coupled to personalized, clinically relevant and easy to interpret results.

Jason Myers, CEO at ArcherDX, highlighted the importance of having an international network of testing labs to support clinical trials services.

"Our biopharma partners look at the market from a global perspective. Given the nature of cancer as a genetic disease and the varying incidence rates in different ethnic groups, it is important to be able to use genomic approaches to identify and enroll patients from around the world."

Guanghui Hu, PhD, President and CEO of Admera, elaborated. "Admera has already been recognized as an innovator in the NGS panel space; however, the ArcherDX CSP program will allow for expanded services.

We are excited to offer ArcherDX's unique fusion detection technology and to provide a comprehensive array of solutions to biopharma customers performing clinical trials and translational research."

Admera Health Oncology products and services enable identification of key medically actionable mutations in solid tumors that are related to targeted therapies and chemotherapeutic response. The addition of Archer FusionPlex assays expands Admera's capabilities to detect novel fusions in cancer, bioinformatically counting individual input molecules to compensate for amplification artifacts.

ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications.

By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry and easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance.

Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.



Source: Company Press Release